Drug Profile
OPX 212
Alternative Names: OPX-212Latest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Opexa Therapeutics
- Developer Acer Therapeutics
- Class Anti-inflammatories; Cell therapies; Eye disorder therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuromyelitis optica
Most Recent Events
- 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neuromyelitis-optica in USA (SC, Injection)
- 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics